PL375697A1 - Pirazolipirymidyny jako inhibitory kinazy zależnej od cykliny - Google Patents

Pirazolipirymidyny jako inhibitory kinazy zależnej od cykliny

Info

Publication number
PL375697A1
PL375697A1 PL03375697A PL37569703A PL375697A1 PL 375697 A1 PL375697 A1 PL 375697A1 PL 03375697 A PL03375697 A PL 03375697A PL 37569703 A PL37569703 A PL 37569703A PL 375697 A1 PL375697 A1 PL 375697A1
Authority
PL
Poland
Prior art keywords
compounds
cyclin
pyrazolopyrimidines
kinase inhibitors
dependent kinase
Prior art date
Application number
PL03375697A
Other languages
English (en)
Other versions
PL224879B1 (pl
Inventor
Timothy J. Guzi
Kamil Paruch
Michael P. Dwyer
Ronald J. Doll
Viyyoor Moopil Girijavallabhan
Alan Mallams
Carmen S. Alvarez
Kartik M. Keertikar
Jocelyn Rivera
Tin-Yau Chan
Vincent Madison
Thierry O. Fischmann
Lawrence W. Dillard
Vinh D. Tran
Zhen Min He
Ray Anthony James
Haengsoon Park
Vidyadhar M. Paradkar
Douglas Walsh Hobbs
Original Assignee
Schering Corporation
Pharmacopeia Drug Discovery, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation, Pharmacopeia Drug Discovery, Inc. filed Critical Schering Corporation
Publication of PL375697A1 publication Critical patent/PL375697A1/pl
Publication of PL224879B1 publication Critical patent/PL224879B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

W wielu wykonaniach niniejszy wynalazek dostarcza nowej klasy pirazolo[1,5-a]pirymidynowych związków jako inhibitorów zależnych od cykliny kinaz, sposobów wytwarzania takich związków, farmaceutycznych kompozycji zawierających jeden lub więcej taki związek, sposobów wytwarzania farmaceutycznych preparatów zawierających jeden lub więcej taki związek i sposobów leczenia, zapobiegania, hamowania lub łagodzenia jednej lub więcej chorób związanych z CDK z użyciem takich związków albo farmaceutycznych kompozycji.
PL375697A 2002-09-04 2003-09-03 Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja PL224879B1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40802702P 2002-09-04 2002-09-04
US60/408,027 2002-09-04
US42195902P 2002-10-29 2002-10-29
US60/421,959 2002-10-29

Publications (2)

Publication Number Publication Date
PL375697A1 true PL375697A1 (pl) 2005-12-12
PL224879B1 PL224879B1 (pl) 2017-02-28

Family

ID=31981560

Family Applications (1)

Application Number Title Priority Date Filing Date
PL375697A PL224879B1 (pl) 2002-09-04 2003-09-03 Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja

Country Status (12)

Country Link
EP (1) EP2194058B1 (pl)
JP (1) JP2010180234A (pl)
AR (1) AR041137A1 (pl)
CY (1) CY1110666T1 (pl)
DE (1) DE60332846D1 (pl)
EC (2) ECSP055642A (pl)
ES (1) ES2346204T3 (pl)
MY (1) MY138201A (pl)
PL (1) PL224879B1 (pl)
PT (1) PT1537116E (pl)
RU (1) RU2380369C9 (pl)
TW (1) TWI344468B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278910B2 (en) * 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
BR112015031040A8 (pt) 2013-06-11 2018-01-02 Receptos Inc Novos moduladores do receptor de glp-1
JP2017538711A (ja) 2014-12-10 2017-12-28 セルジーン インターナショナル ツー エスエーアールエル Ｇｌｐ−１レセプターモジュレーター
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN108431008A (zh) 2015-11-19 2018-08-21 蓝图药品公司 可用于治疗与ntrk相关的病症的化合物和组合物
US20190151324A1 (en) 2016-06-23 2019-05-23 University Of Maryland, Baltimore NON-CATALYTIC SUBSTRATE-SELECTIVE P38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF
CN113395963B (zh) 2018-12-07 2024-06-25 马里兰大学巴尔的摩分校 非ATP/催化位点p38丝裂原活化蛋白激酶抑制剂
AU2021274475B2 (en) 2020-05-18 2024-03-21 Gen1E Lifesciences Inc. P38alpha mitogen-activated protein kinase inhibitors
CA3213095A1 (en) 2021-03-23 2022-09-29 Adam Galan Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907799A (en) 1971-08-16 1975-09-23 Icn Pharmaceuticals Xanthine oxidase inhibitors
AU7997091A (en) 1990-05-30 1991-12-31 American Home Products Corporation Substituted arylsulfonamides and benzamides
ES2126573T3 (es) 1991-04-22 1999-04-01 Otsuka Pharma Co Ltd Derivado de pirazol (1,5-a)pirimidina y agente antiinflamatorio que contiene este derivado.
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
US5707997A (en) 1994-06-21 1998-01-13 Otsuka Pharmaceutical Factory, Inc. Pyrazolo 1,5-a!pyrimidine derivative
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AU747705C (en) * 1997-12-13 2004-09-23 Bristol-Myers Squibb Company Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
PT997474E (pt) 1998-08-14 2004-01-30 Pfizer Agentes antitromboticos
AU752186B2 (en) 1998-10-30 2002-09-12 Merck & Co., Inc. Thrombin inhibitors
CA2352505C (en) 1998-12-22 2009-04-07 Novartis Ag Epothilone derivatives and their use as antitumor agents
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
JP2003505384A (ja) 1999-07-15 2003-02-12 ファーマコピーア，インコーポレーティッド ブラジキニンｂ１受容体アンタゴニスト
CA2417254A1 (en) 2000-07-26 2002-02-07 Bristol Myers Squibb Company N-¢5-¢¢¢5-alkyl-2-oxazolyl!methyl!thio!-2-thiazolyl! carboxamide inhibitors of cyclin dependent kinases
HUP0302991A3 (en) 2000-09-15 2009-10-28 Vertex Pharma Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
EP1345941A1 (fr) 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors

Also Published As

Publication number Publication date
MY138201A (en) 2009-05-29
RU2005109543A (ru) 2006-05-10
EP2194058B1 (en) 2013-11-27
ECSP11005642A (es) 2011-10-31
DE60332846D1 (de) 2010-07-15
RU2380369C2 (ru) 2010-01-27
EP2194058A1 (en) 2010-06-09
TWI344468B (en) 2011-07-01
ECSP055642A (es) 2005-05-30
ES2346204T3 (es) 2010-10-13
TW200410973A (en) 2004-07-01
PT1537116E (pt) 2010-09-03
CY1110666T1 (el) 2015-06-11
RU2380369C9 (ru) 2011-07-10
JP2010180234A (ja) 2010-08-19
AR041137A1 (es) 2005-05-04
PL224879B1 (pl) 2017-02-28

Similar Documents

Publication Publication Date Title
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NO20051647L (no) Pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY137888A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
TW200407322A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
HK1112233A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer
MY162134A (en) Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
WO2007058873A3 (en) Imidazopyrazines as cyclin depentend kinase inhibitors
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HK1065033A1 (en) Thiazole compounds useful as inhibitors or proteinkinases
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
TH148526B (th) ไพราโซโลไพริมิดีนชนิดใหม่ (Novel pyrazolopyrimidines) ล่าสุดในฐานะตัวยับยั้งไซคลินดีเพนเดนท์คิเนส (Cyclin dependent kinase inhibitors)